Welcome to our dedicated page for Astronics SEC filings (Ticker: ATRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avionics power systems, LED cabin lighting, and complex test benches make Astronics� disclosures anything but light reading. Each quarter the company explains how shifting commercial and defense demand flows through its Aerospace and Test Systems divisions, embeds segment data deep inside tables, and reports dozens of R&D programs. If you have ever tried to trace program backlog or margin trends across multiple exhibits, you already know the challenge.
Stock Titan solves that hurdle by turning every Astronics filing into plain language. Our AI reads the entire document in seconds, highlighting what matters and linking directly to source pages. Use it to answer questions investors type every day, such as Astronics SEC filings explained simply or understanding Astronics SEC documents with AI.
- Track Astronics insider trading Form 4 transactions and receive Astronics Form 4 insider transactions real-time alerts before the market closes.
- Dive into each Astronics quarterly earnings report 10-Q filing; our summary extracts segment sales, program backlog, and cash-flow details.
- Read the Astronics annual report 10-K simplified to spot long-cycle defense contracts, warranty reserves, and debt covenants without wading through footnotes.
- Get instant context when a sudden press release triggers an Astronics 8-K material events explained note.
- Review the latest Astronics proxy statement executive compensation to compare CEO pay, incentive metrics, and option grants.
- Benchmark trends with concise Astronics earnings report filing analysis generated by our quantitative models.
- Stay on top of Astronics executive stock transactions Form 4 to identify buying or selling patterns.
Every document�10-K, 10-Q, 8-K, S-8, or Form 4—appears on this page the moment it hits EDGAR. Paired with expert commentary, shareable charts, and smart search filters, Stock Titan lets professionals make informed decisions in less time. No more scrolling through 300-page PDFs; the insight you need is already distilled and waiting.
Astronics Corporation (ATRO) disclosed transactions and accounting presentation changes in a Current Report on Form 8-K. The company may repurchase outstanding 2030 notes in individually negotiated transactions, which could lead holders to buy common stock in open market transactions to unwind hedges and potentially place upward pressure on Astronics' stock price. Astronics also stated intent to pursue a cash flow-based revolving credit facility to replace its existing credit agreement, but provided no assurances that such a facility will be secured or on favorable terms. Separately, Astronics changed its presentation of research and development costs in Q1 2025, moving R&D out of Cost of Products Sold into a separate line item and furnished supplemental historical R&D, cost of products sold, and gross profit data for 2022�2024 for comparability.
Mark Peabody, Executive VP & President - Aerospace at Astronics Corp. (ATRO), reported changes in his beneficial ownership on Form 4. The filing shows transactions dated 08/13/2025 including dispositions: 450 shares of common stock and 183,994 shares of Class B stock. The report lists his remaining direct holdings and outstanding equity awards, including multiple stock options exercisable through 2033 and several restricted stock unit grants tied to average annual adjusted EBITDA performance periods spanning 2023�2027, with vesting ranges specified. The form is signed by Julie Davis as Power of Attorney for Mr. Peabody.
Linda O'Brien, a director of Astronics Corporation (ATRO), received 6,055 shares of common stock upon settlement of restricted stock units and increased her direct holdings to 19,839 shares. The filing shows 6,055 restricted stock units settled into shares at no cash price, and an additional 1,200 shares are reported as indirectly owned through her spouse. The transaction was reported on the Form 4 and executed under code M, with the shares added to her direct beneficial ownership.
This disclosure documents an insider equity settlement rather than an open-market purchase or sale, showing management compensation converted into common stock and clarifying both direct and spousal indirect ownership positions.
Jeffry D. Frisby, a director of Astronics Corporation (ATRO), received and settled restricted stock units into common stock on August 27, 2025. The filing shows Frisby was issued 6,055 restricted stock units that were settled for 6,055 shares of common stock at no cash price ($0 listed). After the transaction, Frisby beneficially owned 47,523 shares of Astronics common stock. The Form 4 was signed by a power of attorney on August 28, 2025.
Robert S. Keane, a director of Astronics Corporation (ATRO), reported transactions dated 08/27/2025 on a Form 4. He received 6,055 shares of common stock through the settlement of restricted stock units at no cash cost ($0 per share). After the settlement, Mr. Keane directly beneficially owned 12,401 shares of common stock.
The filing discloses material indirect holdings: 206,886 Class B shares (reported as indirect via Note 1) and 208,199 Class B shares (reported as indirect via Note 2). The filing explains these indirect interests arise from a trust and an LLC (Boston & Saranac LLC) that ultimately list Mr. Keane and his spouse as beneficiaries, with the reporting person’s proportionate interest below 25% of the trust.
Mark J. Moran, a director of Astronics Corp (ATRO), received 6,055 shares of common stock upon settlement of restricted stock units on 08/27/2025. The Form 4 shows these restricted stock units converted to common shares and recorded as an acquisition (transaction code M) with an indicated price of $0 and an ownership form marked Direct. After the settlement, Mr. Moran beneficially owned 42,523 shares. The filing was signed via power of attorney on 08/28/2025.
Robert T. Brady, a director of Astronics Corp (ATRO), reported transactions on August 27, 2025. The filing shows 6,055 restricted stock units were settled into 6,055 shares of common stock at no cash price. The report also lists dispositions of 85,069 common shares and 175,076 Class B shares (both shown as disposed). Brady retains several outstanding stock options and previously granted restricted units that were exercised or settled; option exercise prices and expiration dates are shown in the filing. The form was signed by a power of attorney on behalf of Brady.
Warren C. Johnson, a director of Astronics Corporation (ticker ATRO), reported transactions dated 08/27/2025. The filing discloses the settlement of 6,055 restricted stock units into shares of common stock on that date. The Form 4 lists existing derivative holdings consisting of stock options that convert into common and Class B shares: two option grants exercisable through 03/02/2028 and two exercisable through 03/07/2027 or 09/07/2027, covering 8,000 underlying common shares plus 1,200 underlying Class B shares in total. The report was signed by a power of attorney on 08/28/2025. The filing states the restricted stock units were settled for shares on the transaction date.
Astronics Corp director Fay West received 6,055 shares of common stock through the settlement of 6,055 restricted stock units on 08/27/2025. The Form 4 shows the restricted stock units were settled into shares and the reporting person beneficially owned 6,055 shares following the transaction. The filing was submitted by one reporting person and signed by Julie Davis as power of attorney on 08/28/2025. The transaction is recorded with a reported price of $0 (reflecting the RSU settlement) and is a routine equity award settlement by an insider.
Astronics Corp director Neil Y. Kim received 6,055 restricted stock units that were settled into common shares on 08/27/2025. The settlement increased his direct beneficial ownership to 42,523 shares. The Form 4 shows the RSUs were granted and settled as part of compensation (transaction code M) and recorded at a nominal price of $0 with a $0.01 par value reference. The filing also lists outstanding stock options exercisable through 2027 and 2028 with exercise prices of $28.50 and $34.04, and convertible/plan-designated shares tied to those options. The Form 4 was signed by a power of attorney on behalf of Mr. Kim on 08/28/2025.